NEW YORK (GenomeWeb News) – Epigenetics-based cancer test developer PrognosDx has named Joseph Vallner to be its new CEO. Vallner, who formerly was president and COO at Cell Genesys, will succeed founding President and CEO Kamran Tahamtanzadeh, who will continue to serve as chairman of the board of directors.

The company is preparing to launch its PrognoScore test to predict clinical outcomes and assess risk probabilities for prostate cancer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

Wired reports that 23andMe is trying to bolster its outside collaborations.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.